The Phase III Checkmate-548 trial (NCT02667587), which investigated the addition of nivolumab to standard of care in the setting of MGMT-methylated relpased GBM, also failed to meet its primary end point of increased survival [71]. Here, MGMT is linked to glioblastoma.